Search research articles
Contact Us
Filters
Showing results (141-150 of 149) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 149 results.
Pediatrics
|
November 29, 2002
Longitudinal, 15-year follow-up of children born at less than 29 weeks' gestation after introduction of surfactant therapy into a region: neurologic, cognitive, and educational outcomes
Carl T D'Angio, Robert A Sinkin, Timothy P Stevens, et al.
Bone Marrow Transplantation
|
February 5, 2008
Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies
P Niscola, C Romani, L Scaramucci, et al.
Pediatrics
|
May 13, 1998
School-age follow-up of prophylactic versus rescue surfactant trial: pulmonary, neurodevelopmental, and educational outcomes
R A Sinkin, B M Kramer, J L Merzbach, et al.
Acta Diabetologica
|
February 21, 2025
Attending an integrated nephrology and diabetology outpatient service can improve diabetic kidney disease treatment: a single-center experience
S Wolde Sellasie, C Pecchioli, K Cersosimo, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
September 1, 1996
Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas
G B Ratto, S Toma, D Civalleri, et al.
Circulation
|
August 2, 2000
Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia
L H Gowdak, L Poliakova, X Wang, et al.
ESMO Real World Data and Digital Oncology
|
April 3, 2026
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study
M E Cazzaniga, V Cogliati, E Rossi, et al.
Breast (Edinburgh, Scotland)
|
July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
M E Cazzaniga, M Airoldi, V Arcangeli, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|
July 9, 2013
[Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]
V Saglimbene, D D'Alonzo, M Ruospo, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 149) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 149 results.
Pediatrics
|
November 29, 2002
Longitudinal, 15-year follow-up of children born at less than 29 weeks' gestation after introduction of surfactant therapy into a region: neurologic, cognitive, and educational outcomes
Carl T D'Angio, Robert A Sinkin, Timothy P Stevens, et al.
Bone Marrow Transplantation
|
February 5, 2008
Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies
P Niscola, C Romani, L Scaramucci, et al.
Pediatrics
|
May 13, 1998
School-age follow-up of prophylactic versus rescue surfactant trial: pulmonary, neurodevelopmental, and educational outcomes
R A Sinkin, B M Kramer, J L Merzbach, et al.
Acta Diabetologica
|
February 21, 2025
Attending an integrated nephrology and diabetology outpatient service can improve diabetic kidney disease treatment: a single-center experience
S Wolde Sellasie, C Pecchioli, K Cersosimo, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
September 1, 1996
Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas
G B Ratto, S Toma, D Civalleri, et al.
Circulation
|
August 2, 2000
Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia
L H Gowdak, L Poliakova, X Wang, et al.
ESMO Real World Data and Digital Oncology
|
April 3, 2026
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study
M E Cazzaniga, V Cogliati, E Rossi, et al.
Breast (Edinburgh, Scotland)
|
July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
M E Cazzaniga, M Airoldi, V Arcangeli, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|
July 9, 2013
[Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]
V Saglimbene, D D'Alonzo, M Ruospo, et al.
Page
of 15